Novartis
970.80
-9.75(-0.99%)
Market Cap₹2,421.10 Cr
PE Ratio24.90
IndustryHealthcare
Company Performance:
1D-0.99%
1M+6.54%
6M+10.86%
1Y+20.28%
5Y+76.14%
View Company Insightsright
More news about Novartis
26Feb 26
Novartis India Receives Detailed Public Statement for ₹552.49 Crore Open Offer
Novartis India Limited has received the detailed public statement from WaveRise Investments Limited and its consortium partners for their mandatory open offer to acquire 26% voting share capital at ₹860.64 per share. The comprehensive transaction includes underlying share purchase agreement for 70.68% stake acquisition from Novartis AG, with tendering period scheduled from April 21 to May 5, 2026.
 no imag found
20Feb 26
Novartis AG Executes Sale Agreement for 70.68% Stake in Novartis India with Consortium
Novartis AG has formally executed a sale and purchase agreement with a consortium comprising WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners for the complete divestment of its 70.68% stake in Novartis India Limited. The transaction involves 1,74,50,680 shares with differentiated pricing structures and will result in Novartis AG ceasing to be a promoter while the acquirers gain control and new promoter status, subject to mandatory open offer requirements under SEBI regulations.
 no imag found
28Jan 26
Novartis India Reports 37% Decline in Q3 Net Profit to ₹161 Million
Novartis India Limited posted disappointing third-quarter results with net profit declining 37% to ₹161 million from ₹254 million year-on-year. Revenue also contracted 8% to ₹859 million compared to ₹930 million in the same quarter last year. The results indicate challenging market conditions for the pharmaceutical company's Indian operations.
 no imag found
21Jan 26
Novartis CEO Vas Narasimhan Expects AI Benefits for Pharmaceutical Sector in 7-10 Years
Novartis CEO Vas Narasimhan expects the pharmaceutical sector to see tangible AI benefits within 7-10 years, with the company's Hyderabad facility serving as a key innovation hub. The CEO emphasized cost optimization goals and faster medicine delivery through AI technology, while expressing satisfaction with current workforce levels in India. Narasimhan also highlighted the importance of modernizing India's Ayushman Bharat system for broader patient access and revealed significant investments in neuroscience research targeting conditions like Huntington's, Parkinson's, and Alzheimer's disease.
 no imag found
30Dec 25
Novartis India Board Meeting on January 28, 2026 for Q3FY26 Financial Results
Novartis India Limited has officially announced its Board of Directors meeting scheduled for January 28, 2026, to consider and approve Q3FY26 unaudited financial results. The company has implemented a trading window closure from January 1, 2026, for designated persons in compliance with SEBI regulations, with reopening 48 hours after results declaration.
 no imag found
28Oct 25
Novartis India Reports Robust Q2 Performance with 33% EBITDA Growth
Novartis India Limited announced its Q2 FY2026 financial results, showing significant improvements. Revenue increased by 4% to ₹903.00 crore, EBITDA grew by 33% to ₹239.00 crore, and net profit rose by 19% to ₹242.00 crore. The company's EBITDA margin expanded by 582 basis points to 26.44%. The Board of Directors met on October 28, 2025, to approve these results.
 no imag found
29Jul 25
Novartis India Reports Q1 Results, Appoints Cost Auditors
Novartis India Limited reported Q1 revenue of ₹875.50 crore, down 5.1% year-over-year but up 4.4% quarter-over-quarter. Profit increased 7.3% year-over-year to ₹276.20 crore. The company appointed M/s. D.C. Dave & Co. as Cost Auditors for the upcoming fiscal year, with a remuneration of ₹1.50 lakh plus taxes, subject to shareholder approval via postal ballot.
 no imag found
09May 25
Novartis India Reports Robust Q4 Results, Declares ₹25 Dividend
Novartis India Limited has released its Q4 financial results, showing significant improvements across key metrics. Revenue increased by 3.36% to ₹839.00 crore. EBITDA more than doubled to ₹239.00 crore, with the EBITDA margin expanding to 28.49%. Net profit surged by 99.59% to ₹293.00 crore. The company's board has recommended a dividend of ₹25.00 per equity share.
 no imag found
Novartis
970.80
-9.75
(-0.99%)
1 Year Returns:+20.28%
Industry Peers
Sun Pharmaceutical
1,757.20
(-2.03%)
Divis Laboratories
5,947.00
(-0.84%)
Torrent Pharmaceuticals
4,220.20
(-1.06%)
Dr Reddys Laboratories
1,254.90
(-2.09%)
Lupin
2,313.90
(-0.90%)
Cipla
1,224.20
(-1.46%)
Zydus Life Science
871.20
(-2.84%)
Mankind Pharma
2,005.80
(-1.62%)
Aurobindo Pharma
1,304.40
(-0.75%)
Alkem Laboratories
5,299.00
(-0.85%)